Recent Posts
- Allosite Therapeutics to Present Four Posters at American Society of Nephrology Kidney Week 2025
- AlloSite Therapeutics launches
- Acquisition of clinical stage integrin activator program from Gossamer Bio
- Nomination of integrin α3β1 as a target for its unique agonist antibodies as therapeutics for kidney disease
Recent Comments